3-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, 97%, 250mg

2,4-Dibromobenzoyl chloride, 95.0%, 1g

n-(2-(1h-Indol-3-yl)ethyl)-2-aminoacetamide, 95%, 1g

4-(Pentafluorosulfanyl)phenyldiazonium Tetrafluoroborate>98.0%(HPLC)5g

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methylhex-5-enoic acid, 95.0%, 1g

N1,N1'-(Butane-1,4-diyl)bis(propane-1,3-diamine) tetrahydrochloride, 95.0%, 1g

FMOC-3-METHYL-L-PHENYLALANINE, 95%, 100g

1,2-Ethanedithiol>99.0%(GC)500g

GC capillary column ROTI®Cap-1701, 15 m, 0.32 mm, 0.25 µm, 1 Piece(s)

11-(2-Chloroacetyl)-5H-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11H)-one, 99.0%, 5g

Methyl 3-(2-methoxypyridin-4-yl)-3-oxopropanoate, 95%, 250mg

But-2-enoic anhydride, 95.0%, 5g

Arachidonic acid, >99%, 100 mg, glass packaging